Skip to main content

Advertisement

Table 5 Serum cytokines concentration before and after NK cell therapy

From: Phase I clinical trial of autologous NK cell therapy using novel expansion method in patients with advanced digestive cancer

  Baseline (day 0) (pg/ml) Post administration (day 42) (pg/ml) p value
IL-1β 4.007 ± 7.155 6.438 ± 13.22 0.25
IL-1RA 893.3 ± 2154 983.0 ± 2550 1
IL-2 37.16 ± 22.54 37.45 ± 29.48 0.8203
IL-4 2.456 ± 0.6683 2.600 ± 0.7691 0.4961
IL-5 4.029 ± 2.191 4.171 ± 3.156 1
IL-6 38.62 ± 47.26 45.43 ± 58.69 0.3594
IL-7 3.827 ± 3.984 4.724 ± 6.224 0.8203
IL-8 26.94 ± 9.571 30.73 ± 16.71 0.4258
IL-9 31.33 ± 28.77 32.87 ± 37.69 0.4258
IL-10 26.28 ± 30.72 27.71 ± 39.37 0.3008
IL-12p70 37.28 ± 50.31 47.22 ± 83.46 0.9102
IL-13 14.87 ± 21.99 19.05 ± 36.70 0.8203
IL-15 44.33 ± 20.73 43.67 ± 28.17 0.8203
IL-17 199.2 ± 89.43 185.1 ± 109.2 0.4961
IFN-γ 92.13 ± 119.4 105.4 ± 141.8 0.3594
TNF-α 32.04 ± 45.28 38.69 ± 59.64 0.0977
bFGF 51.92 ± 31.51 53.38 ± 45.84 0.7344
PDGF-BB 172.2 ± 108.3 191.0 ± 219.0 0.9102
G-CSF 55.23 ± 26.89 58.08 ± 40.79 0.9102
GM-CSF 90.58 ± 75.85 94.29 ± 97.23 0.7344
IP-10 287.1 ± 40.88 389.2 ± 204.4 0.3008
MCP-1 133.6 ± 33.18 122.1 ± 52.29 0.2031
MIP-1α 4.972 ± 3.239 4.214 ± 2.073 0.1641
MIP-1β 275.0 ± 86.68 300.6 ± 154.0 1
Eotaxin 116.4 ± 193.8 123.2 ± 233.4 0.7344
RANTES 2157 ± 396.8 2445 ± 580.7 0.2031
VEGF 92.02 ± 30.85 113.2 ± 79.16 0.9102
  1. Values are expressed as the mean ± SD. The paired t test was used to determine statistical differences
  2. NS not significant